Results 231 to 240 of about 106,022 (294)

Semaglutide and Resmetirom in Patients With Metabolic Dysfunction‐Associated Steatohepatitis and Fibrosis: An Exploratory Indirect Comparison

Diabetes, Obesity and Metabolism, EarlyView.
Alessandro Mantovani, Giovanni Targher
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?

Circulation
Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combination therapies is approaching magnitudes achieved with surgery.
Jennifer Linge, Andreas Birkenfeld, Ian Neeland   +2 more
exaly   +2 more sources

Glucagon-like Peptide-1 Receptor Agonists

Stroke Revisited, 2021
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have been used to treat patients with type 2 diabetes mellitus (T2DM) since exenatide, the first GLP-1RA, was approved in 2005. GLP-1 is a peptide hormone secreted by L cells of the small intestine in response to nutrients.
J. Jeon, H. Kim
semanticscholar   +2 more sources

Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists.

JAMA
This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA discontinuation; and calls for the identification and implementation of ...
Sadiya S Khan, C. Ndumele, Dhruv S. Kazi
semanticscholar   +3 more sources

Glucagon-Like Peptide-1 Receptor Agonists

Reactions Weekly
Highlights: Introduction Pharmacology Treatment Advantages/Disadvantages Therapeutic Considerations Monographs ...
Heather P. Whitley, Jennifer M. Trujillo
  +11 more sources

Glucagon-like peptide-1 receptor agonists

, 2016
Native glucagon-like peptide-1 (GLP-1) is not practical for therapeutic use due to a short half-life caused by ubiquitous, fast, and effective in vivo degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).
B. Gallwitz
semanticscholar   +2 more sources

Overview of Glucagon-like Peptide-1 Receptor Agonists

Home Healthcare Now, 2015
Type 2 diabetes mellitus is an increasingly prevalent disease in the United States and globally. Multiple pharmacologic therapies are typically required over time to achieve and maintain target blood glucose levels. When first-line oral medications such as metformin (Glucophage) are not effective in achieving desired glycosylated hemoglobin (HbA1C ...
Laura, Steadman, Joan S, Grant, Lucinda J, Graven   +2 more
openaire   +2 more sources

Effect of glucagon‐like peptide‐1 receptor agonists on body weight in adults with obesity without diabetes mellitus—a systematic review and meta‐analysis of randomized control trials

Obesity Reviews, 2022
Clinical trials have investigated the weight loss effect of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) in adults with obesity without diabetes mellitus, but results for weight loss efficacy were varied.
Junaid Iqbal, Hui-Xuan Wu, Nan Hu, Ying-Hui Zhou, Long Li, Fen Xiao, Ting Wang, Hong-Li Jiang, Shi-Na Xu, Bi-Ling Huang, Houde Zhou   +10 more
semanticscholar   +1 more source